Exelixis (EXEL) Bank of America Global Healthcare Conference summary

Intellectual property and legal matters

• Ongoing patent litigation remains unresolved, with no new updates; the company continues to defend its IP vigorously.

• Settlements with Teva and Cipla set a key generic entry date at January 1, 2031.

• Patent protection, including pediatric extension, could last until early 2027, depending on outcomes.

Commercial performance and growth drivers

• Product revenues and royalties are around $2 billion, with recent market share growth in RCC despite competition.

• Growth in the core RCC franchise is slowing, but new indications are expected to drive reacceleration from 2025 onward.

• Recent ESMO data presentations in NET and prostate cancer support future growth opportunities.

• FDA submission for a new indication has been accepted, with a PDUFA date in April next year.

Market opportunities and product expansion

• NETs present a substantial market opportunity due to high unmet need and favorable disease dynamics.

• The company is optimistic about becoming a market leader in NETs, leveraging existing commercial infrastructure.

• The prescriber base for NETs overlaps significantly with current users, facilitating market entry.